Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DHACOTCMKTS:RNVANASDAQ:VSEEOTCMKTS:VYNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDHACDigital Health Acquisition$1.26+7.1%$1.17$11.07▼$33.08$4.54M0.2340,215 shs90,252 shsRNVARennova Health$0.00$0.00▼$0.00$4.31M18.542.98 million shsN/AVSEEVsee Health$1.14+4.1%$1.16$1.00▼$14.47$4.09MN/A1.03 million shs21,369 shsVYNTVyant Bio$0.19+7.8%$0.19$0.14▼$1.58$1.23M1.73161,822 shs19,100 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDHACDigital Health Acquisition0.00%-1.56%+2.44%-2.33%-94.00%RNVARennova Health0.00%0.00%0.00%0.00%0.00%VSEEVsee Health-2.68%-17.41%-10.73%-7.63%+108,999,900.00%VYNTVyant Bio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDHACDigital Health AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ARNVARennova HealthN/AN/AN/AN/AN/AN/AN/AN/AVSEEVsee Health0.9081 of 5 stars2.03.00.00.00.60.00.0VYNTVyant BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDHACDigital Health Acquisition 0.00N/AN/AN/ARNVARennova Health 0.00N/AN/AN/AVSEEVsee Health 4.00Strong Buy$5.00340.53% UpsideVYNTVyant Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDHACDigital Health AcquisitionN/AN/AN/AN/AN/AN/ARNVARennova Health$18.69M0.00N/AN/AN/ANaNVSEEVsee Health$6.38M0.64N/AN/A($3.40) per share-0.33VYNTVyant Bio$670K1.83N/AN/A$1.69 per share0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDHACDigital Health AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ARNVARennova Health-$7.73MN/A0.00N/AN/AN/AN/AN/AN/AVSEEVsee Health-$4.41MN/A0.00∞N/AN/A-182.59%-58.26%6/5/2025 (Estimated)VYNTVyant Bio-$22.69MN/A0.00∞N/A-3,474.81%-151.82%-97.14%N/ALatest VYNT, DHAC, VSEE, and RNVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/5/2025N/AVSEEVsee Health-$0.09-$0.12-$0.03N/A$3.52 million$3.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDHACDigital Health AcquisitionN/AN/AN/AN/AN/ARNVARennova HealthN/AN/AN/AN/AN/AVSEEVsee HealthN/AN/AN/AN/AN/AVYNTVyant BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDHACDigital Health AcquisitionN/AN/AN/ARNVARennova HealthN/AN/AN/AVSEEVsee Health0.160.370.37VYNTVyant Bio0.042.862.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDHACDigital Health Acquisition1.01%RNVARennova HealthN/AVSEEVsee Health1.01%VYNTVyant BioN/AInsider OwnershipCompanyInsider OwnershipDHACDigital Health Acquisition6.59%RNVARennova Health55.52%VSEEVsee Health6.59%VYNTVyant Bio9.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDHACDigital Health Acquisition2,0213.60 million3.37 millionNot OptionableRNVARennova Health6043.05 billion32.36 billionNot OptionableVSEEVsee HealthN/A3.60 million3.37 millionN/AVYNTVyant Bio306.33 million5.72 millionNot OptionableVYNT, DHAC, VSEE, and RNVA HeadlinesRecent News About These CompaniesBio vs non-bio washing powderAugust 7, 2024 | which.co.ukWhat is Biotechnology?August 4, 2024 | bio.orgVyant Bio files Certificate of Dissolution with State of DelawareDecember 26, 2023 | msn.comVyant Bio Inc VYNTDecember 19, 2023 | morningstar.comVyant Bio, Inc.: Vyant Bio Provides Update on Winddown ActivitiesNovember 11, 2023 | finanznachrichten.deVyant Bio expects to start liquidation payments in Q4 2024November 10, 2023 | msn.comVyant Bio Provides Update on Winddown ActivitiesNovember 10, 2023 | finance.yahoo.comVyant Bio, Inc.: Vyant Bio Announces Stockholder Approval of Plan of DissolutionNovember 1, 2023 | finanznachrichten.deVyant Bio shareholders approve plan to dissolve companyNovember 1, 2023 | msn.comVyant Bio Announces Stockholder Approval of Plan of DissolutionNovember 1, 2023 | finance.yahoo.comNamtu Airport, Namtu, Myanmar [ NMT / VYNT ]October 28, 2023 | prokerala.comLab Notes: Philadelphia health care investment firm closes two funds valued at over $500MOctober 26, 2023 | finance.yahoo.comVyant Bio, Inc.: Vyant Bio Announces Completion of StemoniX Asset SaleOctober 25, 2023 | finanznachrichten.deVyant Bio Announces Completion of StemoniX Asset SaleOctober 24, 2023 | finance.yahoo.comVyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of StockholdersOctober 19, 2023 | finance.yahoo.comVyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of StockholdersOctober 11, 2023 | finance.yahoo.comVyant Bio, Inc.: Vyant Bio Announces Adjournment of Special Meeting of StockholdersSeptember 30, 2023 | finanznachrichten.deVyant Bio Announces Adjournment of Special Meeting of StockholdersSeptember 20, 2023 | finance.yahoo.comMedicare patients took unnecessary genetic cancer tests in man’s $463M scheme, feds sayAugust 21, 2023 | yahoo.comScientists identify four new breast cancer risk genesAugust 21, 2023 | devdiscourse.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVYNT, DHAC, VSEE, and RNVA Company DescriptionsDigital Health Acquisition NASDAQ:DHAC$1.26 +0.08 (+7.07%) As of 05/30/2025Digital Health Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on technology and healthcare focused businesses. Digital Health Acquisition Corp. was incorporated in 2021 and is based in Boca Raton, Florida.Rennova Health OTCMKTS:RNVARennova Health, Inc., together with its subsidiaries, provides health care services in the United States. It owns one operating hospital in Oneida, Tennessee; and a rural clinic in Williamsburg, Kentucky. The company is based in West Palm Beach, Florida.Vsee Health NASDAQ:VSEE$1.14 +0.05 (+4.13%) As of 02:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.VSee Health, Inc. is a no-code or low-code software as a service (SaaS) platform that enables clinicians and enterprises to create their telehealth workflows without programming. It engages in providing timely, quality healthcare to patients regardless of geographical barriers. The company is headquartered in Boca Raton, FL.Vyant Bio OTCMKTS:VYNT$0.19 +0.01 (+7.78%) As of 12/29/2023Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
